# A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer

> **NCT06935175** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Hepatocellular Cancer

## Interventions

- **DRUG:** SHR-1826
- **DRUG:** SHR-1826 and immunotherapy combination therapy

## Key facts

- **NCT ID:** NCT06935175
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05-01
- **Primary completion:** 2027-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06935175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06935175, "A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT06935175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*